With news of Axovant’s big failure in Alzheimer’s, the drug industry is looking ahead to its next major crack at the disease — and it’s a long wait.
In 2019, three large, late-stage Alzheimer’s trials are expected to read out, providing what could be the final word on a trio of drugs that scientists and analysts say represent the next best hope of breaking the industry’s generation of failure in the field.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
